The results of the new drug trial for lung disease are mixed, Sanofi (SNY.US) and Regeneron (REGN.US) both fell in pre-market trading.

According to the Securities Times app, before the opening of the US stock market on Friday, Sanofi (SNY.US) fell 6.17% and Regeneron (REGN.US) fell 13.77%. On the news front, the experimental drug from the two companies for a fatal lung disease had mixed results.